Bain's Orly Mishan joins Pfizer's neuro spinout Cerevel; Oncolytic virus biotech taps SillaJen exec Helena Chaye as CEO
→ Bain Capital is deploying one of its top investors to Cerevel Therapeutics, steering a $350 million-plus neuro play carved out of Pfizer. Orly Mishan — a co-founder and principal of Bain’s life sciences unit — was involved in the partnership that birthed the biotech spinout in the first place. As Cerevel’s first chief business officer, she is tasked with corporate development, program management as well as technical operations.
Cerevel launched last October after Adam Koppel spearheaded a deal to spin the neurosciences programs Pfizer had abandoned (alongside 300 staffers) out to a new, well funded company. Since then it’s been building out its own team, filling the leadership ranks with alumni of Sangamo, Otsuka and Mer ...